Points are given to cases of breast or ovarian cancer on the same side of a family, with additional points added or subtracted based on tumour pathology; a Manchester score of 15 equates to a 10% likelihood of detecting an underlying BRCA1/2 variant and a score of 20 to a 20% likelihood. This evidence concerns the gene BRCA1 and ovarian cancer.